The Transformative Healthcare at Foresite Capital by Jim Tananbaum

The Foresite Capital is a for-profit health care company that offers its services to both public and private medical centers. It is based in San Francisco. Foresite Capital has directly invested in Mindstrong Health along with others like the Optum Ventures, One Mind Brain Health Impact Fund, and ARCH Venture Partners.

In a report by Patient Daily, the drive fund will help in the diagnosis, treatment, and management of Neuropsychiatric disorders as Jim Tananbaum, the CEO of Foresite Capital puts it. The Mindstrong Technology uses a smart phone app that objectively measures the cognitive health disorders hence prompt care given to the ailing person. Paul Dagun, the Founder, and CEO of Mindstrong Health say the system will improve the mental disorder management. For more details visit Bloomberg

Mindstrong Health boasts about its innovative professionals who are experienced, have unquestionable leadership capabilities and have a clear vision and target. From the pre-trial clinical test conducted, the community would benefit immensely if the organization was to function optimally. Dr. Tom Insel, the Mindstrong Health along with Jim sees this platform where modernity and health care interplay for the benefit of all. The platform operates like the human brain has high resolution and is feed with information to tell of the mental disorders that relate to its functioning, speed, and memory. Check out LinkedIn to know more.

About Jim Tananbaum

Jim Tanabaum is the founding CEO of the Foresite Capital, a leading company in the health care services and support. With his impressive experience in the pharmaceutical industry where he has previously worked for, this was a well-informed venture to take his medical career upwards to continue serving the people. He is an accomplished scholar having gone through the Yale University for an engineering degree, then a medical degree from the Harvard Medical School and an MBA from the Harvard Business School.

He has worked with some great pharmaceutical companies such as the Geltex and the Theravance before co-founding the Foresite Capital. Jim has played the advisory role on the boards of the Yale School of Engineering, Harvard MIT-HST Program, Amerigroup, Tarsa Therapeutics, Amira Pharmaceuticals and Jazz Pharmaceuticals. Through him over 21 healthcare companies have benefited from Foresite Capital services.

Click here: https://www.facebook.com/public/Jim-Tananbaum

Categories: Health Research

Clinical Excellence: CAA of Austin, Texas

When it comes to providing the very best of medical care, Capital Anesthesiology Association is at the top of most people’s list. This organization has been around since the early 70’s and it delivers on all promises. Unfortunately, many other medical facilities doesn’t have the patients best interest at heart. If money is the motive, any organization will most certainly lose it’s way. Not to worry with CAA because this team of highly qualified medical personnel does everything by the book, are very professional, and practices at the highest quality of standards. This ensures any and all patients that they will be receiving the very best of services that gets them back up on their feet and running.

Capital Anesthesiology Association has many doctors and nurses that are board certified under the American Board of Anesthesiology. This isn’t by chance either as each and every staff member is highly trained and educated, which gives the patient the best possible outcome for his or her situation. Whether it’s for ambulatory surgical centers, or for high acuity hospitals, as well as level 1 trauma centers, CAA delivers on all promises.

Clinical excellence? Of course, CAA has the very best talented doctors and nurses whom are truly ethical. You won’t find any blemishes here even if you look through a microscope. The future is here and Capital Anesthesiology Association is leading the way by example.

A Short History of the Medical Journal Oncotarget

The medical journal Oncotarget, which is published by Impact Journals, is a peer-reviewed online publication that is released on a weekly basis. It was first released in 2010 and is provided in an open access format. Dr. Mikhail Blagosklonny and Dr. Andrei V. Gudkov founded Oncotarget and are the journal’s editors-in-chief.

Oncotarget got its name from being originally focused on the field of oncology. In 2017 the journal was opened up to featuring research papers that come from other fields of medicine like Endocrinology, Metabolism, and Cell Biology. This was done in order to better meet the mission of the magazine, part of which includes breaking down the existing barriers between different medical specialties. The mission of Oncotarget also includes making medical research broadly and rapidly available as well promoting clinical science into diseases. The eventual goal of the journal is life without disease. Oncotarget is published by Impact Journals

Both Dr. Gudkov and Dr. Blagosklonny work at the Roswell Park Cancer Institute which is based in Buffalo, New York. Both are cancer researchers and have each written a great many research papers themselves. Dr. Blagosklonny is also a Professor of Oncology at the institute. Dr. Gudkov serves as the Senior Vice President of Basic Science Chair as well as the Garman Family Chair in Cell Stress Biology. Dr. Gudkov holds 27 medical patents and has either authored or co-authored over 135 scientific research papers.

The editorial board of Oncotarget is made up of professionals across the United States that are working at both universities and hospitals. Among the institutions that have personnel on Oncotarget’s editorial board are John Hopkins University, St Jude’s Children’s Research Hospital, the California Institute of Technology, The Scripps Research Institute, and the Lawrence Berkeley National Laboratory.

Oncotarget uses the COPE Code of Conduct as the basis of its ethics and malpractice practices, as well as the Best Practices Guidelines for Journal Editors. These rules are in place so that everyone involved in publishing research articles is held to the strictest ethical codes. The COPE Code of Conduct applies to authors, reviewers, editors, and publishers. Oncotarget is also available on Dove Press.

Categories: Health Research